肝胆相照论坛

标题: Novira宣布任命罗杰·J·波默朗茨,医学博士作为科学顾问委员 [打印本页]

作者: StephenW    时间: 2014-8-27 16:50     标题: Novira宣布任命罗杰·J·波默朗茨,医学博士作为科学顾问委员

Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board

Published: Aug 26, 2014 8:00 a.m. ET

DOYLESTOWN, Pa., Aug. 26, 2014 /PRNewswire/ -- Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that Roger J. Pomerantz, M.D., F.A.C.P., was appointed the Chair of its Scientific Advisory Board (SAB). In this role he will also function as a Senior Advisor to the Company.

"We are thrilled to have Roger join our SAB as Chair," said Christian Schade, Chief Executive Officer at Novira.  "Roger brings a wealth of pharma and biotech experience in drug development which will be invaluable to Novira as we continue to advance NVR-1221, our novel HBV core inhibitor program, currently in clinical development for chronic HBV infection."

Dr. Pomerantz added, "I very much look forward to working with the Novira team and members of the SAB as they continue to develop this very important compound. NVR-1221 leads a new class of antiviral agents that may offer a curative approach to patients with chronic HBV infection."

Dr. Pomerantz is President, Chief Executive Officer and Chairman of Seres Health and was Senior Vice President and Worldwide Head of Licensing & Acquisitions at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Roger was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. He has been responsible for leading the development of 8 approved drugs for HIV, HCV and MDR-TB. Previously, Roger received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School and was selected and served as the Chief Medical Resident at M.G.H. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology. Roger was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School.

About NVR-1221

NVR-1221 is a small molecule, direct-acting antiviral, for oral administration in patients with Chronic Hepatitis B (CHB) that inhibits the HBV core or capsid protein. HBV core is a novel and promising drug target with multiple activities required for viral replication and persistence. Inhibition of HBV core protein function by NVR-1221 offers the potential for a more efficient suppression of the virus leading to improved durable viral suppression and functional cure rates.

NVR-1221 is in Phase 1a clinical studies in New Zealand following successful completion of the Clinical Trial Application (CTA) regulatory process. The Phase 1a clinical study will investigate the dose-related safety/tolerance and pharmacokinetics (PK) of NVR-1221 in approximately 40 healthy volunteers. Upon completion and satisfactory outcome of the Phase 1a clinical study, Novira will commence a Phase 1b clinical study to test the safety, PK and initial antiviral activity of NVR-1221 in patients with chronic HBV infection.

作者: StephenW    时间: 2014-8-27 16:51

Novira治疗宣布任命罗杰·J·波默朗茨,医学博士,作为科学顾问委员会主席

发布时间:2014年8月26日上午08时00 ET

多伊尔斯敦,宾夕法尼亚州,2014年8月26日/新华美通/ - 。Novira Therapeutics公司是一家私人持有的生物制药公司,开发开发新疗法的治疗治疗慢性乙型肝炎病毒(HBV)感染,今天宣布,罗杰·J·波默朗茨,医学博士,亚洲文化推展联盟,被任命其科学顾问委员会的主席(SAB)。在这个职位上,他也将作为一个高级顾问公司。

“我们很高兴能有罗杰加入我们的SAB作为主席,”基督教夏德,首席执行官Novira说。 “罗杰带来了丰富的制药和生物技术药物发展Novira经验,这将是非常宝贵的,我们将继续推动NVR-1221我们的新型HBV核心抑制剂方案,目前正处于临床开发用于治疗慢性HBV感染。”

波默朗茨博士补充说,“我非常期待着与球队Novira和SAB的成员,因为他们继续开发这一非常重要的化合物。NVR-1221会导致一类新的抗病毒药物可能提供的治疗方法,患者慢性HBV感染者“。

波默朗茨博士为主席,行政总裁及卫生委员会主席,并为赛里斯高级牌照和收购的默克制药公司的副总裁兼全球主管,他负责监督所有许可和收购默克研究实验室。此前,他曾担任高级副总裁及传染病默克公司的全球连锁加盟负责人。在加入默克,罗杰是传染病的强生制药,负责全球所有抗感染药的全球负责人。他加入强生公司于2005年,Tibotec公司制药公司总裁,他一直负责领导8批准的药物为HIV,HCV和耐多药结核病的发展。此前,罗杰接受了他的学士学位生物化学在约翰斯·霍普金斯大学和他的医师在医学的约翰·霍普金斯大学。他完成了内科实习和住院医师培训哈佛医学院,他的临床和科研专科培训,传染病和病毒在美国马萨诸塞州总医院(MGH)和被选择并担任首席医疗​​居民在麻省总医院他的博士后研究培训分子反转录病毒学得同时在哈佛医学院和麻省理工学院Whitehead研究所。罗杰是医学教授,生物化学与分子药理学,传染病主任和创始主任和人权研究所病毒学主席和生物防御的托马斯杰斐逊大学医学院。

关于NVR-1221

NVR-1221是一种小分子,直接作用抗病毒药物,用于口服治疗慢性乙型肝炎(CHB)抑制HBV核心或衣壳蛋白。 HBV核心是一种新颖的和有前途的药物靶标和病毒复制所需的和持久的多个活动。乙肝病毒核心蛋白的功能由NVR-1221的抑制提供了可能让他们从而提高了耐用的病毒抑制和功能治愈率病毒的更有效的抑制。

NVR-1221是在新西兰1a期临床研究在成功完成临床试验申请(CTA)的监管过程。 1A阶段的临床研究将探讨NVR-1221,大约40名健康志愿者的剂量相关的安全性/耐受性和药代动力学(PK)。建成后,一期工程1A临床研究,疗效满意,Novira将开始执行一项1b期临床研究,以测试在慢性HBV感染者的NVR-1221的安全性,PK和初始抗病毒活性。
作者: newchinabok    时间: 2014-8-27 18:47

大公司,有实力,方向对,值得长期关注




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5